DNA damage response inhibitors, including PARPi, have shown promising results, particularly in Ewing sarcoma, an STS affecting adolescents and young adults bearing EWS-FLI1 or EWS-ERG genomic fusions with the EWS-FLI1 oncoprotein increasing PARP expression2,58. This evidence concerns the gene FLI1 and telomere syndrome.